Clinical Trial Update: VK2735 for Weight Management Phase 2 [Phase 2]

View source ↗

Summary

VK2735, Viking Therapeutics' weight-management drug candidate, completed a Phase 2 study for weight loss.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• VK2735

Snippet

Sponsor: Viking Therapeutics, Inc. | Conditions: Weight Loss | Phase 2 | Status: COMPLETED